Genmab A/S (NASDAQ:GMAB) receives new price target of $39.00 at SVB Leerink

Genmab A/S (NASDAQ: GMAB) saw its price target lowered by SVB Leerink from $42.00 to $39.00 in a report on Thursday, Target Stock Advisor reports. The company currently has a “market performance” rating on the stock. SVB Leerink’s target price would indicate a potential upside of 16.28% from the company’s current price.

Several other equity research analysts have also published reports on GMAB. Berenberg Bank began covering Genmab A/S in a research note on Wednesday, December 1. They issued a “sell” rating for the company. HC Wainwright upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a price target of $47.00 for the company in a Monday, January 31 research note. Guggenheim downgraded Genmab A/S from a “buy” rating to a “neutral” rating in a research note on Monday, January 3. Ultimately, Zacks Investment Research downgraded Genmab A/S from a “hold” rating to a “sell” rating in a Thursday, January 20 research note. Four analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned the company a buy rating. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $45.71.

Genmab A/S shares opened at $33.54 on Thursday. The stock has a 50-day moving average of $36.18 and a 200-day moving average of $41.30. Genmab A/S has a 12-month low of $30.10 and a 12-month high of $49.07. The company has a market capitalization of $22.04 billion, a PE ratio of 47.91, a PEG ratio of 1.72 and a beta of 1.03.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Institutional investors and hedge funds have recently increased or reduced their stakes in the company. Arrowstreet Capital Limited Partnership increased its equity stake in Genmab A/S by 4,355.2% in Q3. Arrowstreet Capital Limited Partnership now owns 427,699 shares of the company valued at $18,690,000 after acquiring an additional 418,099 shares during the period. Royal Bank of Canada increased its holdings of Genmab A/S shares by 10.3% in Q2. Royal Bank of Canada now owns 584,745 shares of the company valued at $23,875,000 after acquiring an additional 54,420 shares during the period. FORA Capital LLC bought a new position in shares of Genmab A/S in the 2nd quarter at a value of $105,000. FourThought Financial LLC increased its position in Genmab A/S shares by 17.9% in the third quarter. FourThought Financial LLC now owns 10,508 shares of the company worth $459,000 after purchasing an additional 1,593 shares in the last quarter. Finally, First Trust Advisors LP acquired a new equity stake in Genmab A/S in Q2 valued at $19,618,000. Institutional investors hold 6.49% of the company’s shares.

About Genmab A/S

Genmab A/S operates as an international biotechnology company. The company develops therapeutic human antibodies for the treatment of cancer and other diseases. Its product portfolio includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.

See also

Stock Target Advisor Logo

Analyst Recommendations for Genmab A/S (NASDAQ: GMAB)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Genmab A/S right now?

Before you consider Genmab A/S, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Genmab A/S was not on the list.

Although Genmab A/S currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.